Leeper Christine M, Vissa Madhav, Cooper James D, Malec Lynn M, Gaines Barbara A
Division of General Surgery and Trauma, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania.
Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26415. Epub 2017 Jan 9.
Pediatric trauma patients are at high risk for development of venous thromboembolism (VTE). Our objective is to describe incidence, risk factors, and timing of development of VTE, anticoagulation complications, and long-term VTE outcomes in a critically injured pediatric population.
We did a retrospective review of pediatric (0-17 years) trauma admissions to intensive care unit from 2005 to 2014. Our center employs VTE screening and prevention protocols for high-risk patients based on hypercoagulable history, age, injuries, and medical interventions. We collected demographics, VTE prevention measures, VTE incidence, therapeutic anticoagulant use, and outcomes including postthrombotic syndrome (PTS) and clot resolution. Analysis included Wilcoxon rank-sum, Fisher exact, and logistic regression modeling.
Seven hundred fifty-three subjects were analyzed. No patients on chemical prophylaxis (21/753) developed VTE. Overall incidence of deep vein thrombosis (DVT) was 8.9%; pulmonary embolism (PE) was 0%. Time to diagnosis was median (interquartile range [IQR]) 10.5 (6.5-14.5) days, with 63% of clots being symptomatic. Risk factors for VTE development included severe traumatic brain injury (TBI), acute traumatic coagulopathy (defined by elevated admission international normalized ratio), age less than or equal to 3 or age 13 years or more, injury severity, and child abuse mechanism. At a median (IQR) follow-up of 13 (6-19) months, 52.1% had persistent clot and 15.8% had PTS. Therapeutic anticoagulation was not associated with clot resolution or prevention of PTS.
TBI therapy is closely linked to the development of DVT. Coagulopathy on admission is associated with hypercoagulability in the postinjury period, suggesting a patient phenotype with systemic coagulation dysregulation. Treatment was not associated with improved VTE outcomes, suggesting that pediatric protocols should emphasize VTE prevention and prophylaxis strategies.
儿科创伤患者发生静脉血栓栓塞症(VTE)的风险很高。我们的目的是描述重症受伤儿科人群中VTE的发生率、风险因素、发生时间、抗凝并发症以及长期VTE结局。
我们对2005年至2014年入住重症监护病房的儿科(0至17岁)创伤患者进行了回顾性研究。我们的中心根据高凝病史、年龄、损伤情况和医疗干预措施,为高危患者采用VTE筛查和预防方案。我们收集了人口统计学数据、VTE预防措施、VTE发生率、治疗性抗凝药物的使用情况以及包括血栓后综合征(PTS)和血栓溶解在内的结局。分析包括Wilcoxon秩和检验、Fisher精确检验和逻辑回归建模。
共分析了753名受试者。接受化学预防的患者(21/753)中无一人发生VTE。深静脉血栓形成(DVT)的总体发生率为8.9%;肺栓塞(PE)的发生率为0%。诊断时间的中位数(四分位间距[IQR])为10.5(6.5 - 14.5)天,63%的血栓有症状。VTE发生的风险因素包括严重创伤性脑损伤(TBI)、急性创伤性凝血病(通过入院时国际标准化比值升高定义)、年龄小于或等于3岁或13岁及以上、损伤严重程度以及虐待儿童机制。在中位(IQR)随访13(6 - 19)个月时,52.1%的患者血栓持续存在,15.8%的患者出现PTS。治疗性抗凝与血栓溶解或PTS的预防无关。
TBI治疗与DVT的发生密切相关。入院时的凝血病与伤后高凝状态相关,提示存在全身凝血调节异常的患者表型。治疗与改善VTE结局无关,这表明儿科方案应强调VTE预防和预防策略。